Evidence map›Paper›PMID 39191494›Full record

ArticleCancer genomics & proteomics

Worse Wilms' Tumor Outcomes Associated With Chemical Complementarity for Multiple T-Cell Receptor CDR3-CMV Epitope Pairs.

Kasey L Rigby, Michael J Diaz, Etienne C Gozlan, Dorottya B Kacsoh, Joanna J Song, Tabitha R Hudock, Andrea Chobrutskiy, Boris I Chobrutskiy, George Blanck

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer genomics & proteomics. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. High-throughput, quantitative approach to peptide epitope discovery.Medical & biological engineering & computing · 2026
    Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Kasey L RigbyUniversity of Central Florida College of Medicine, Orlando, FL, U.S.A.
Michael J DiazDepartment of Molecular Medicine, Morsani College of Medicine, University of South Florida, Tampa, FL, U.S.A.
Etienne C GozlanDepartment of Molecular Medicine, Morsani College of Medicine, University of South Florida, Tampa, FL, U.S.A.
Dorottya B KacsohUniversity of Central Florida College of Medicine, Orlando, FL, U.S.A.
Joanna J SongDepartment of Molecular Medicine, Morsani College of Medicine, University of South Florida, Tampa, FL, U.S.A.
Tabitha R HudockDepartment of Molecular Medicine, Morsani College of Medicine, University of South Florida, Tampa, FL, U.S.A.
Andrea ChobrutskiyDepartment of Pediatrics, Oregon Health and Science University Hospital, Portland, OR, U.S.A.
Boris I ChobrutskiyDepartment of Internal Medicine, Oregon Health and Science University Hospital, Portland, OR, U.S.A.
George BlanckDepartment of Molecular Medicine, Morsani College of Medicine, University of South Florida, Tampa, FL, U.S.A.; gblanck@usf.edu.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND/

aimWilms' tumors are pediatric renal tumors that generally have a good prognosis and outcomes. Viral illnesses have been linked to development of neoplasms and should be considered as a factor that could modulate overall survival. MATERIALS AND

methodsWe considered recently developed adaptive immune receptor, genomics and bioinformatics approaches to assess the potential impact of cytomegalovirus (CMV) infections in Wilms' tumor.

resultsT-cell receptor (TCR) complementarity determining region-3 (CDR3) amino acid sequences from Wilms' tumor specimens represented by the Therapeutically Applicable Research to Generate Effective Treatments dataset were compared with known anti-CMV TCR CDR3s, indicating that cases representing the anti-CMV TCR CDR3s had worse outcomes. Then, a chemical complementarity scoring approach for the Wilms' tumor, TCR CDR3s and a series of CMV antigens further indicated that cases representing a higher chemical complementarity to the CMV antigens had worse outcomes.

conclusionOverall, we present a potentially novel method to assess CMV infections and identify patients who could benefit from therapies that address such infections.

Indexed as

Complementarity Determining RegionsCytomegalovirusKidney NeoplasmsReceptors, Antigen, T-CellWilms TumorCytomegalovirus InfectionsEpitopesHumansPrognosisComplementarity Determining RegionsEpitopesReceptors, Antigen, T-Cellcomplementarity determining region-3cytomegalovirusRNAseq filesT-cell receptorWilms’ tumor

Identifiers

PMID39191494
PMCPMC11363928

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.